April 16, 2021
FDA approves first immunotherapy for initial treatment of gastric cancer
On April 16, 2021,
the
U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination
with certain types of chemotherapy, for the initial treatment of patients with
advanced or metastatic gastric cancer, gastroesophageal junction cancer and
esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the
first-line treatment of gastric cancer.